- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07685522
Vibrato Aspiration System - Simple, Intuitive Approach to Clot Removal in Acute Pulmonary Embolism - a Safety & Feasibility Study
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The study objective is to evaluate the safety and effectiveness of the Vibrato™ Aspiration System Aspiration System (hereafter referred to as Vibrato™ Aspiration System) for aspiration mechanical thrombectomy in the treatment of acute PE.
The Vibrato™ Aspiration System is a vibration-assisted aspiration thrombectomy device including attributes designed to improve trackability, maintain a low-profile configuration, and operate without capital equipment. In addition, the Vibrato™ Aspiration System features a novel vibrating distal tip designed to enhance thrombus removal during aspiration while minimizing vascular injury. The vibrating mechanism may reduce procedure times, improve clot removal efficiency, and decrease the need for adjunctive interventions.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Shawn M Patterson
- Número de telefone: 7164323545
- E-mail: spatterson@egrethealthcareventure.com
Estude backup de contato
- Nome: Erin M Garcia
- Número de telefone: 716-863-2552
- E-mail: egarcia@egrethealthcareventures.com
Locais de estudo
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polônia, 61-848
- Ainda não está recrutando
- Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny
-
Investigador principal:
- Aleksander Araszkiewicz, Professor, MD, PhD
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polônia, 31-202
- Recrutamento
- Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
-
Investigador principal:
- Grzegorz Kopeć, Professor, MD, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
Subjects must meet all following general inclusion criteria:
- Age ≥ 18 and ≤ 75 years.
- Clinical signs, symptoms, and presentation consistent with acute PE;
- PE symptom duration ≤ 14 days;
- CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
- RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined).
- Systolic blood pressure ≥ 90 mmHg;
- Stable heart rate < 130 BPM prior to procedure;
- Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment
- Informed Consent Form signed
- Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit
Exclusion Criteria:
Subjects must not meet any of the following general exclusion criteria:
- Thrombolytic use within 30 days of baseline CT angiogram
- Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
- Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg;
- FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%;
- Hematocrit < 28%;
- Platelets < 100,000/ML;
- Serum creatinine > 1.8 mg/dL;
- International normalized ratio (INR) > 3;
- Major trauma injury severity score (ISS) > 15 within the past 14 days
- Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators;
- Cardiovascular or pulmonary surgery within last 7 days;
- Actively progressing cancer requiring chemotherapy
- Known bleeding diathesis or coagulation disorder;
- Left bundle branch block;
- History of severe or chronic pulmonary arterial hypertension;
- History of chronic left heart disease with left ventricular ejection fraction ≤ 30%;
- History of uncompensated heart failure;
- History of underlying lung disease that is oxygen dependent;
- History of chest irradiation;
- History of heparin-induced thrombocytopenia (HIT);
- Patients who are under intubation
- Any contraindication to systemic or therapeutic doses of heparin or anticoagulants;
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated;
- Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention;
- Life expectancy of < 90 days, as determined by Investigator;
- Female who is pregnant or nursing;
- Current participation in another investigational drug or device treatment study
- History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
- Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Viabilidade do dispositivo
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Single arm study
Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute pulmonary embolism.
|
Mechanical Thrombectomy for the treatment of Acute Pulmonary Embolism
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety Endpoint: Major Adverse Events
Prazo: 48 hours
|
Major Adverse Events, a composite of:
|
48 hours
|
|
Efficacy Endpoint: Reduction in RV/LV Ratio
Prazo: 48 hours
|
Reduction in RV/LV ratio from baseline to 48 hours or discharge by CT angiography
|
48 hours
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety Endpoint: Device-Related Death
Prazo: 48 hours
|
Device-related death within 48 hours
|
48 hours
|
|
Safety Endpoint: Major Bleeding
Prazo: 48 Hours
|
Major bleeding within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Clinical Deterioration
Prazo: 48 Hours
|
Device-related clinical deterioration within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Pulmonary Vascular Injury
Prazo: 48 Hours
|
Device-related pulmonary vascular injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Cardiac Injury
Prazo: 48 Hours
|
Cardiac injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Any-Cause Mortality
Prazo: 30 Days
|
Any-cause mortality within 30 days
|
30 Days
|
|
Safety Endpoint: Device-Related Serious Adverse Event
Prazo: 30 Days
|
Device-related Serious Adverse Events (SAEs) within 30 days
|
30 Days
|
|
Safety Endpoint: Symptomatic Recurrence of Pulmonary Embolism
Prazo: 30 Days
|
Symptomatic recurrence of Pulmonary Embolism (PE) within 30 days
|
30 Days
|
|
Efficacy Endpoint: Modified Miller Index Score
Prazo: 48 Hours
|
Change in modified Miller Index Score (MMIS) between baseline and 48 hours post-procedure as assessed by CTA
|
48 Hours
|
|
Efficacy Endpoint: Change in Mean Pulmonary Artery Pressure
Prazo: Procedure
|
Change in mean pulmonary artery pressure measured invasively in the central pulmonary arteries before vs. after the endovascular procedure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Change in Cardiac Index
Prazo: Procedure
|
Procedural change in cardiac index [measured in L/min/m^2]
|
Procedure
|
|
Efficacy Endpoint: Length of ICU Stay, Associated with Index Procedure
Prazo: 30 Days
|
Length of stay in the ICU associated with the index procedure [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Length of Total Hospital Stay
Prazo: 30 Days
|
Length of total hospital stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Post-Index Procedure Hospital Length of Stay
Prazo: 30 Days
|
Post-index-procedure hospital length of stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Mean Pressure
Prazo: Procedure
|
Procedural reduction in pulmonary artery mean pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Systolic Pressure
Prazo: Procedure
|
Procedural reduction in pulmonary artery systolic pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Reduction in Total Pulmonary Vascular Resistance
Prazo: Procedure
|
Procedural reduction in total pulmonary vascular resistance [measured in mmHg ⋅ min/L]
|
Procedure
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Prazo: 48 Hours
|
Change from baseline in Dyspnea severity by mMRC score at the 48-hour visit
|
48 Hours
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Prazo: 30 Days
|
Change from baseline in Dyspnea severity by mMRC score [Time Frame: at the 30 days visit]
|
30 Days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 26-VIC-0001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .